Article Abstract

Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population

Authors: Haifeng Qin, Fang Wang, Ke Wang, Hui Liu, Rui Guo, Zhen Zeng, Xin Pan, Xiaofeng Fu, Ting Zhang, Hongjun Ga


Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of refractory rash and pruritus in Chinese malignancy population. patients showed a rapid recovery from refractory pruritus, no adverse events occurred. Weekly follow-up visits showed the pruritus were stable and no further episodes was recorded.